Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma (REGO-SARC)

• ClinicalTrials.gov Identifier: NCT01900743
• Recruitment Status: Completed
• First Posted: July 16, 2013
• Last Update Posted: April 9, 2021
• Sponsor: Centre Oscar Lambret
• Collaborator: Bayer
• Information provided by (Responsible Party): Centre Oscar Lambret

Tracking Information

• First Submitted Date: July 9, 2013
• First Posted Date: July 16, 2013
• Last Update Posted Date: April 9, 2021
• Actual Study Start Date: June 5, 2013
• Actual Primary Completion Date: September 16, 2020 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 30, 2018)

Progression-free survival (PFS) [ Time Frame: Up to 2 years ]

Progression-Free Survival will be measured from the date of randomization until the date of radiological progression or death (if death occurs before progression). Progression-free rate at 3 and 6 months (PFR-3 and PFR-6), time to progression, response rate and duration of response, overall survival according to RECIST 1.1 criteria

• Original Primary Outcome Measures (submitted: July 12, 2013): To evaluate the progression-free survival (PFS) [ Time Frame: Up to 2 years ]

Current Secondary Outcome Measures (submitted: March 30, 2018)

• Growth modulation index [ Time Frame: Up to 2 years ]
  Growth modulation index in patients receiving regorafenib after randomization
• Toxicity according to NCI-CTC AE V4.0. [ Time Frame: Baseline, every 4 weeks, up to the end of study ]
  The monitoring of the toxicity of the regorafenib which can have a liver toxicity for exemple.
• Progression-free rate at 3 and 6 months (PFR-3 and PFR-6) [ Time Frame: At month 3 and at month 6 ]
  According to the RECIST 1.1
• Time to progression [ Time Frame: Up to 2 years ]
  According to the RECIST 1.1 Every 4 weeks, Up to 2 years
• Overall survival [ Time Frame: Up to 2 years ]
  Time from the date of randomization to the date of death from any cause
• Response rate [ Time Frame: Up to 2 years ]
  the proportion of patients with the best overall tumor response of partial response (PR) or complete response (CR) according to RECIST 1.1 guidelines that is achieved during treatment or within 30 days after termination of study medication.
• Duration of response [ Time Frame: Up to 2 years ]
  the number of days from the date of first documented objective response of PR or CR, whichever is noted earlier, to first disease progression or death before progression. Patients without progression or death before progression at the time of analysis will be censored at the date of their last tumor assessment.

Original Secondary Outcome Measures (submitted: July 12, 2013)

• To explore the growth modulation index in patients receiving regorafenib after randomization [ Time Frame: Up to 2 years ]
• To evaluate toxicity according to NCI-CTC AE V4.0. [ Time Frame: Baseline, every 4 weeks, up to the end of study ]
• To evaluate progression-free rate at 3 and 6 months (PFR-3 and PFR-6) [ Time Frame: At month 3 and at month 6 ]
  According to the RECIST 1.1
• To evaluate time to progression [ Time Frame: Up to 2 years ]
  According to the RECIST 1.1 Every 4 weeks, Up to 2 years
• To evaluate overall survival [ Time Frame: Up to 2 years ]
  Time from the date of randomization to the date of death from any cause
• To evaluate response rate [ Time Frame: Up to 2 years ]
• To evaluate duration of response [ Time Frame: Up to 2 years ]

Current Other Pre-specified Outcome Measures (submitted: March 30, 2018)

Potential predictive factors for regorafenib response. [ Time Frame: Up to 2 years ]

The monitoring of the factors which can induce a regorafenib response (Formalin fixed, paraffin embedded (FFPE) or fresh frozen tissue samples collected either from the primary tumor or from metastatic sites, or both will be analyzed)

• Original Other Pre-specified Outcome Measures (submitted: July 12, 2013): To identify potential predictive factors for regorafenib response. [ Time Frame: Up to 2 years ]

Descriptive Information

• Brief Title: Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
• Official Title: Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial

Brief Summary

This is an international (France, Austria and Germany), randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of regorafenib in patients with histologically proven metastatic and/or unresectable Soft Tissue Sarcoma (STS) after failure or intolerance to doxorubicin (or other anthracycline).

Five cohorts will be defined:

Cohort A: Liposarcoma Cohort B: Leiomyosarcoma Cohort C: Synovial sarcoma Cohort D: other sarcomas (see Appendix C) Cohort E: Leiomyosarcoma, Synovial sarcoma and other sarcomas listed in Appendix C previously treated with pazopanib Approximately 226 patients who meet the eligibility criteria will be randomly assigned in a 1:1 ratio to one of the treatment groups.

Detailed Description

The standard of care for metastatic soft tissue sarcoma is doxorubicin +/- ifosfamide. After failure or intolerance to doxorubicin, there is no standard of care. In Europe, two are currently approved for the treatment of soft tissue sarcoma after failure/intolerance to doxorubicin: trabectedin (Yondelis®) for all histological subtype and pazopanib (Votrient ®) for all subtypes excluding liposarcomas. Nevertheless, none of these drugs improve the overall survival over placebo.

The study is composed of 3 periods:

1. A Screening Period,
2. A Treatment Period,
3. And a Survival Follow-up Period. Patients randomized to be treated with regorafenib will receive the treatment orally for 3 weeks of every 4 week (28 days) cycle (ie, 3 weeks on/1 week off).

Patients randomized to the placebo arm will be treated for 3 weeks of every 4 weeks cycle (ie, 3 weeks on/1 week off).

In addition to the regorafenib and placebo treatments, patients will receive best supportive care. Best supportive care includes any method to preserve the comfort and dignity of the patients and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor,chemotherapy, radiation therapy, or surgical intervention.

Patients receiving placebo, who experience disease progression may be offered open-label regorafenib(cross-over option).

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Sarcoma

Intervention

• Drug: Regorafenib
  Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
  Other Name: stivarga
• Drug: Placebo
  Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression

Study Arms

• Experimental: Arm A
  Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.
  Intervention: Drug: Regorafenib
• Placebo Comparator: Arm B
  Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
  Intervention: Drug: Placebo

Publications *

• Penel N, Mir O, Wallet J, Ray-Coquard I, Le Cesne A, Italiano A, Salas S, Delcambre C, Bompas E, Bertucci F, Saada-Bouzid E, Chaigneau L, Chevreau C, Brodowicz T, Decoupigny E, Vanseymortier M, Laroche L, Taieb S, Le Deley MC, Blay JY. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. Eur J Cancer. 2020 Feb;126:45-55. doi: 10.1016/j.ejca.2019.12.001. Epub 2020 Jan 6.
• Longue M, Cabarrou B, Wallet J, Brodowicz T, Roche H, Boher JM, Delord JP, Penel N, Filleron T. The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients. Ann Oncol. 2018 Jul 1;29(7):1588-1593. doi: 10.1093/annonc/mdy168.
• Berry V, Basson L, Bogart E, Mir O, Blay JY, Italiano A, Bertucci F, Chevreau C, Clisant-Delaine S, Liegl-Antzager B, Tresch-Bruneel E, Wallet J, Taieb S, Decoupigny E, Le Cesne A, Brodowicz T, Penel N. REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. Cancer. 2017 Jun 15;123(12):2294-2302. doi: 10.1002/cncr.30661. Epub 2017 Mar 10.
• Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1732-1742. doi: 10.1016/S1470-2045(16)30507-1. Epub 2016 Oct 14.
• Brodowicz T, Liegl-Atzwager B, Tresch E, Taieb S, Kramar A, Gruenwald V, Vanseymortier M, Clisant S, Blay JY, Le Cesne A, Penel N. Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. BMC Cancer. 2015 Mar 14;15:127. doi: 10.1186/s12885-015-1143-y.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: March 30, 2018): 219
• Original Estimated Enrollment (submitted: July 12, 2013): 192
• Actual Study Completion Date: September 16, 2020
• Actual Primary Completion Date: September 16, 2020 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Age ≥18 years
• Histological documentation of soft tissue sarcoma (including uterus)with available Formalin Fixed Paraffin Embedded (FFPE) blocks. Eligible soft tissue sarcomas are non-adipocytic soft tissue sarcomas
• Prior treatment with doxorubicin or other anthracycline. Moreover, patients eligible in the Cohort E must have received pazopanib
• Metastatic disease not amenable to surgical resection with curative intent
• Documentation of progression within the last 6 months
• Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST 1.1.
• Performance status ≤1(ECOG)
• Life expectancy ≤ 3 months
• Adequate bone marrow, renal, and hepatic function:
• INR/PTT ≤1.5 x ULN Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring will be performed until INR/PTT is stable.
• Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy.
• Recovery to NCI-CTCAE v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug/procedure related toxicity (except alopecia, anemia, and hypothyroidism).
• In the assessment of the investigator, patient is able to comply with study requirements
• Signed, IRB-approved written informed consent

Exclusion Criteria:

• More than 3 lines of systemic treatment for metastatic sarcoma
• Histological subtypes listed in Appendix C (especially GIST, osseous sarcoma, embryonal or alveolar rhabdomyosarcoma). Patients with liposarcoma are not eligible in the cohort E
• Primary bone sarcoma
• Prior treatment with regorafenib
• Known history of or concomitant malignancy likely to affect life expectancy in the judgment of the investigator
• Pregnant or breastfeeding patients. Women of childbearing potential must have a pregnancy test performed before start of treatment
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of treatment
• Active cardiac disease including any of the following: Congestive heart failure (NYHA) ≥Class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
• Uncontrolled hypertension (SBP >150 mmHg or diastolic pressure >90 mmHg despite optimal medical management)
• Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism (within the last 6 months)
• Ongoing infection >Grade 2 according to NCI-CTCAE v4.0
• Known history of human immunodeficiency virus (HIV) infection
• Known history of chronic hepatitis B or C
• Patients with seizure disorder requiring medication
• History of organ allograft
• Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event > Grade 3 within 4 weeks of start of treatment
• Non-healing wound, ulcer, or bone fracture
• Renal failure requiring hemo- or peritoneal dialysis
• Dehydration according to NCI-CTC v 4.0 Grade >1
• Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
• Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation, including lactose
• Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
• Inability to swallow, malabsorption condition
• Pleural effusion or ascites that causes respiratory compromise (Grade 2 dyspnea)

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Austria, France

Administrative Information

• NCT Number: NCT01900743
• Other Study ID Numbers: REGO-SARC-1214; 2012-005743-24 ( EudraCT Number )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Centre Oscar Lambret
• Original Responsible Party: Same as current
• Current Study Sponsor: Centre Oscar Lambret
• Original Study Sponsor: Same as current
• Collaborators: Bayer

Investigators

• Study Director: Nicolas PENEL, PhD; Centre Oscar Lambret - France
• Principal Investigator: Thomas BRODOWICZ, PhD; AKH-Wien - Austria

• PRS Account: Centre Oscar Lambret
• Verification Date: April 2021